FDA Advisory Committees Recommend Approval of Abuse-Deterrent Morphine

A joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA voted 18-1 to recommend approval of morphine sulfate extended-release (ER) tablets (Arymo ER, Egalet). Morphine sulfate ER was developed using Egalet’s proprietary Guardian Technology for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are